Using circulating tumor cells as a prognostic indicator in metastatic castration-resistant prostate cancer.

@article{Delacruz2012UsingCT,
  title={Using circulating tumor cells as a prognostic indicator in metastatic castration-resistant prostate cancer.},
  author={Anthony Delacruz},
  journal={Clinical journal of oncology nursing},
  year={2012},
  volume={16 2},
  pages={
          E44-7
        }
}
  • A. Delacruz
  • Published 29 March 2012
  • Medicine
  • Clinical journal of oncology nursing
A more reliable tumor marker is needed as a prognostic indicator in metastatic castration-resistant prostate cancer. Circulating tumor cells (CTCs) are cells that have broken away from a tumor and flow in the bloodstream. Evidence has indicated that the presence of CTCs in the peripheral blood of men with solid malignancies correlates with clinical outcomes. When the CTC number is reduced to fewer than five cells per 7.5 ml of blood, survival outcomes often improve. The relationship between the… 
View on PubMed
cjon.ons.org
9 Citations
Background Citations
4

9 Citations

Citation Type

Citation Type

TRAIL-coated leukocytes that prevent the bloodborne metastasis of prostate cancer.
Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis.
Transcription-Based Molecular Imaging and Gene Therapy for Castration-resistant and Metastatic Prostate Cancer in Translational Models
TLDR
A substantial amount of evidence is presented supporting the pre-clinical and translational use of gene-based imaging and therapeutic vectors to assist the management of patients with advanced, treatment-refractory prostate cancer.
Molecular Markers for Patient Selection and Stratification: Personalized Prognostic Predictive Models
TLDR
The emerging data from US statistics on prostate cancer screening and the early results of the 11-year follow-up European Randomized Study of Screening for Prostate Cancer involving eight countries have evidenced that the main downside to large-scale PSA screening is over-diagnosis of biologically “indolent” cancers.
Advances in cancer stem cell targeting: How to strike the evil at its root
Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery
TLDR
An update of novel clinical tests used in research and clinical diagnostic, as well as of potential tissue or fluid biomarkers provided by extensive proteomic research data are provided.
Separation and capture of circulating tumor cells from whole blood using a bypass integrated microfluidic trap array
TLDR
Results demonstrated that it was possible to capture CTCs from the whole blood of a mouse with full-blown metastasis and the bypass integrated microfluidic trap array could become a useful tool for the early prognosis of cancer metastasis.
lncRNA HotairM1 Depletion Promotes Self-Renewal of Cancer Stem Cells through HOXA1-Nanog Regulation Loop
Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds
TLDR
This review focuses on transcriptional regulation, non-coding RNAs, alternative splicing events and cell adhesion molecules regulation during EMT and summarizes the knowledge with regard to the small potentially druggable molecules capable of modulating EMT for cancer therapy.

References

SHOWING 1-10 OF 11 REFERENCES
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
TLDR
Baseline CTC number was strongly associated with survival, without a threshold effect, which increased further when baseline prostate-specific antigen and albumin were included, and was predictive of survival, with no threshold effect.
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
TLDR
CTC are the most accurate and independent predictor of OS in CRPC, and this data led to Food and Drug Administration clearance of this assay for the evaluation of CRPC.
Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer
TLDR
The analysis of cancer-related alterations at the DNA and protein level from CTCs is feasible in a hospital-based clinical laboratory and the alterations observed in EGFR and AR suggest that the methodology may have a role in clinical decision making.
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.
Circulating tumor cells in solid cancer: Tumor marker of clinical relevance?
TLDR
The most recent findings on CTC are reviewed, and the potential of identification and molecular characterization of the subset of CTC responsible for metastasis development is discussed, to provide clinicians with a unique tool for better stratification of patients’ risk.
Circulating tumor cells (CTC) detection: clinical impact and future directions.
Circulating tumor cells: the 'leukemic phase' of solid cancers.
Detection of the circulating tumor cells in cancer patients.
TLDR
Analysis of the experimental strategies used for determining CTCs with respect to accuracy, sensitivity and reproducibility in cancers of the breast, colon, prostate and melanoma finds the most robust strategies are the PCR-based methods and the CellSearch® system.
Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acet
  • H. Scher, G. Heller, +14 authors J. D. de Bono
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
Using standard definition of CTC conversion, the biomarker panel demonstrated a level of surrogacy for OS by correlating well with survival and in a model-adjusted analysis dramatically attenuating the treatment effect.
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
  • H. Scher, S. Halabi, +17 authors M. Hussain
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
New consensus criteria for eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone are defined, with increasing emphasis on time-to-event end points as decision aids in proceeding from phase II to phase III trials.
...
1
2
...